GlassScriptPhysician profile
Dustin A Krassin
NPI 1730342569
$450.85
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $196 · 2020: $102 · 2021: $130 · 2022: $23.74.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $108.96 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $84.35 | 2019 | |
| Sun Pharmaceutical Industries INC. | $56.63 | 2019-2020 | |
| Ocular Therapeutix, INC. | $50.00 | 2021 | |
| Shire North American Group INC | $49.98 | 2019 | |
| Alcon Vision LLC | $29.86 | 2021 | |
| Novartis Pharmaceuticals Corporation | $23.64 | 2020 | |
| Spark Therapeutics, INC. | $18.10 | 2020 | |
| Biotissue Holdings INC. | $17.31 | 2019 | |
| Sight Sciences, INC. | $12.02 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dustin Krassin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.